On the other hand, an elevated PD-L1 expression on tumor cells facilitates PD-1/PD-L1 binding, thus initiating inhibitory signaling pathways that impair T cell activation and attenuate antitumor immune responses (31, 32). The gene discussed is CD274; the disease is neoplasm.